डोरज़ोलामाइड और टिमोलोल के इंटरैक्शन

Known hypersensitivity to indapamide or to other sulfonamide-derived drugs. (इंडापामाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (एनालाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (एम्पाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (एलोग्लिप्टिन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs. (कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity to this product or to other sulfonamide-derived drugs. (क्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed. (क्लोरोप्रोकेन लेबल, सावधानियां)

Because of the hydrochlorothiazide components, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (क्विनाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Hypersensitivity to sulfonamide derivatives. ▪ Known hypersensitivity to glipizide or any of the product's ingredients ( 4 ). ▪ Hypersensitivity to sulfonamide derivatives ( 4 ). (ग्लिपिज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g. , acute congestive heart failure), excessive alcohol intake, hepatic… (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

• Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. (ग्लिमेपिराइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Kidney stones: avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidosis, or in patients on a ketogenic diet ( 5.13 ) (टोपिरामेट लेबल, चेतावनियां और सावधानियां)

Hypersensitivity Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication. (ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS [see… (डाइक्लोरफेनामाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (डैपाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin-containing products, including JALYN. (ड्यूटास्टेराइड और टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (नेबिवोलोल लेबल, दवाओं के इंटरैक्शन)

Use in patients with known history of an allergic reaction to sulfonamide derivatives. (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (पियोग्लिटाज़ोन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (प्रोटामिन लेबल, बॉक्स्ड चेतावनी)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors. (फेंटरमिन और टोपिरामेट लेबल, चेतावनियां और सावधानियां)

Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (फोसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (फ्लेकेनाइड लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (बिसोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. (मेकामाइलामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic… (मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (मेटाइरोसिन लेबल, चेतावनियां)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (रिवास्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (सिटाग्लिप्टिन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. (सिडोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• In patients who have demonstrated allergic-type reactions to sulfonamides [ see Warnings and Precautions (5.7) ]. (सेलेकॉक्सिब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure ), excessive alcohol intake, hepatic… (सैक्साग्लिप्टिन और मेटफॉर्मिन लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, Addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. (स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

In patients with hypersensitivity to sulfonamide-derived drugs. (हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (आइवाब्राडिन लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (आइसोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

Beta-blockers may decrease effectiveness. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (इंडोमेथासिन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Beta Blockers Nadolol Monitor for adverse reactions. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (एर्गोटामिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Use with caution in patients with a known hypersensitivity to sulfonamides ( 5.8 ) (एल्मोट्रिप्टान लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (एसिटाज़ोलामाइड लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (ऑक्ट्रियोटाइड लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (ऑक्साप्रोज़िन लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Abrupt discontinuation of QLONILIK can cause rebound hypertension with elevated plasma catecholamines, especially with higher doses or concomitant beta-blocker use. (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (ग्लूकागॉन लेबल, दवाओं के इंटरैक्शन)

Zileuton increases propranolol levels and beta-blocker activity. (ज़ाइल्यूटॉन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of ZONISADE with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation ( 7.2 ). (ज़ोनिसामाइड लेबल, दवाओं के इंटरैक्शन)

In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (टरब्यूटालिन लेबल, सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

• During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (डाइहाइड्रोएर्गोटामिन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (ड्रोनेडेरोन लेबल, दवाओं के इंटरैक्शन)

Antihypertensives Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of Naproxen Suspension and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (पाइरिडोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (पाइरिमेथामिन लेबल, दवाओं के इंटरैक्शन)

Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (पाइरोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (पैरासिटामोल और आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (पैसिरियोटाइड लेबल, चेतावनियां और सावधानियां)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (पोनेसिमोड लेबल, चेतावनियां और सावधानियां)

Hypotension may develop in patients given prazosin hydrochloride capsules who are also receiving a beta-blocker such as propranolol. (प्राज़ोसिन लेबल, चेतावनियां)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (प्रोबेनेसिड लेबल, दवाओं के इंटरैक्शन)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (प्रोबेनेसिड और कोल्चिसिन लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

Intervention: Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

• Beta-blockers may decrease effectiveness. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Fosamprenavir calcium should be used with caution in patients with a known sulfonamide allergy. (फोसएम्प्रेनाविर लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (फ्लर्बिप्रोफेन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Beta-blockers: Use with caution. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (मेपिवाकेन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (मेफेनामिक एसिड लेबल, दवाओं के इंटरैक्शन)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (मोटिक्साफोर्टाइड लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

• Beta-blockers: Use with caution. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

…Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (रोपिवाकेन लेबल, चेतावनियां और सावधानियां)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (लेडिपासविर और सोफोसबुविर लेबल, चेतावनियां और सावधानियां)

In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (लेवोसैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (लैकोसामाइड लेबल, चेतावनियां और सावधानियां)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (लैनरियोटाइड लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (लोसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (सेविमेलिन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Beta-blockers: Use with caution. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Beta-blockers: Use with caution. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (सोफोसबुविर और वेल्पाटासविर लेबल, चेतावनियां और सावधानियां)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

As with other beta-blockers, when discontinuation of TENORMIN is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. (एटेनोलोल लेबल, चेतावनियां)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (एडेनोसिन लेबल, दवाओं के इंटरैक्शन)

Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (एनालाप्रिलैट लेबल, दवाओं के इंटरैक्शन)

Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (एमोक्सिसिलिन लेबल, दवाओं के इंटरैक्शन)

Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (एम्पीसिलिन लेबल, दवाओं के इंटरैक्शन)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Effects on the absorption of other beta-blockers have not been determined. (कोलेस्टिपोल लेबल, दवाओं के इंटरैक्शन)

Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (परफेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (पेनिसिलिन G लेबल, दवाओं के इंटरैक्शन)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (फिंगोलिमोड लेबल, दवाओं के इंटरैक्शन)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (बिसोप्रोलोल लेबल, दवाओं के इंटरैक्शन)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (बुमेटेनाइड लेबल, चेतावनियां)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (मिथाइलीन ब्लू लेबल, चेतावनियां और सावधानियां)

Cross-Allergy Cross-allergy may occur when metolazone tablets, USP, are given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone. (मेटोलाज़ोन लेबल, चेतावनियां)

Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). (मेमेंटिन लेबल, दवाओं के इंटरैक्शन)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. (सिल्वर सल्फाडायज़िन लेबल, चेतावनियां और सावधानियां)

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (इब्यूटिलाइड लेबल, दवाओं के इंटरैक्शन)